一、2025年度主要财务数据和指标 证券代码：688079 证券简称：美迪凯 公告编号：2026-006 杭州美迪凯光电科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度的定期报告为准，提请投资者注意投资风险。 单位：万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.上述财务数据及指标为未经审计的合并报表数据，最终数据以公司2025年年度报告中披露数据为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况以及财务状况 公司2025年度实现营业收入66,438.70万元，较上年同期增加17,887.58万元，同比增长36.84%；实现归 属于母公司所有者的净利润-15,501.45万元，较上年同期亏损扩大5,316.87万元；实现归属于母公司所有 者的扣除非经常性损益的净利润-15,786.65万元，较上年同期亏损扩大6,477.93万元。 报告期末公司总资产337 ...

Group 1: Transaction Overview - The company plans to introduce strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership) through its subsidiary Zhejiang Meidikai Optical Semiconductor Co., Ltd. [2] - The board of directors approved the proposal for capital increase and share expansion on December 10, 2025, and the relevant agreements have been signed [3]. Group 2: Transaction Progress - As of the announcement date, the company and related parties have signed the capital increase agreement and shareholder agreement, with a total cash capital increase of RMB 200 million received [3]. - Following the capital increase, the registered capital of the optical semiconductor company will increase from RMB 1,008,888,889 to RMB 1,101,447,503, and the company's shareholding will change to 82.44% [3]. Group 3: Performance Forecast - For the fiscal year 2025, the company expects to achieve approximately RMB 664.26 million in revenue, a year-on-year increase of 36.82% [8]. - The company anticipates a net loss attributable to shareholders of approximately RMB -154.41 million, a decrease of RMB 52.57 million compared to the previous year [8]. - EBITDA is projected to be around RMB 65.29 million, reflecting a year-on-year increase of 19.62% [8]. Group 4: Revenue Growth Factors - The revenue increase is attributed to higher sales in semiconductor packaging and testing, as well as new product launches contributing to additional revenue [14]. - Specific revenue contributions include an increase of approximately RMB 94.32 million from semiconductor packaging and testing and RMB 88.90 million from semiconductor acousto-optics [14]. Group 5: Cost and Expense Increases - The company has incurred higher costs due to stock incentive plans, increased interest expenses from larger borrowings, and rising depreciation costs from fixed asset investments [15][16]. - Research and development expenses have also increased, reflecting the company's commitment to new technologies and products [16].

Core Viewpoint - Medike (688079.SH) expects a significant increase in revenue for 2025, while net profit is projected to decline, indicating a mixed financial outlook for the company [1] Financial Projections - The company anticipates achieving an operating revenue of approximately 664.257 million yuan in 2025, representing an increase of about 178.746 million yuan or 36.82% year-on-year [1] - The projected net profit attributable to the parent company is expected to be around -154.414 million yuan, a decrease of approximately 52.568 million yuan compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is estimated to be around -156.947 million yuan, reflecting a decline of about 63.860 million yuan year-on-year [1] Revenue Drivers - The increase in revenue is primarily driven by a rise in semiconductor packaging and testing sales, which are expected to increase by approximately 94.322 million yuan [1] - Sales from semiconductor acousto-optic products are projected to rise by about 88.898 million yuan [1] - The company will begin mass production and delivery of semiconductor process bonding prisms in November 2025, contributing an additional revenue of around 10.969 million yuan [1] - Small-scale production of MEMS devices (MicroLED, uncooled infrared) is expected to generate an increase in sales revenue of approximately 4.256 million yuan [1]